SpIntellx

Our Journey

Our Purpose

Shaping the Future of Spatially Intelligent Biology
See More. Know More. Power Precision Pathology.

We believe the convergence of unbiased spatial analytics and explainable AI ushers in a new era of precision pathology. The novel insights from our platforms reveal the existence of intermediate cell types and their functional states as well as communications between cells.
We offer software as a service (SaaS) for precision pathology applications harnessing unbiased spatial analytics and explainable AI. It empowers accelerated drug discovery for identifying novel targets, biomarkers and invisible cell types, optimizes clinical trials for precision patient stratification, enables advanced companion diagnostics for radically improving prediction accuracies through deep insights into biological mechanisms of action, and drives personalized therapeutic options for selecting optimal therapeutics based on insights into probable patient outcomes.

Our Milestones

2018
Company Formed
2019
HistoMapr SBIR Awarded
2020
  • Nature Communications Publication
  • Advances in Anatomic Pathology Publication
  • Partnership with CellNetix Pathology and Laboratories
2021
  • Cell Reports Methods Publication
  • Partnership with Allegheny Health Network
  • Investment from Innovation Works
  • First Patent Awarded
2022 – Q1-Q2
  • Initial Commercialization
  • USCAP 2022 & AACR 2022 Exhibitor/Presenter

2018

Company Formed

2019

HistoMapr SBIR Awarded

2020

Nature Communications Publication
Advances in Anatomic Pathology Publication
Partnership with CellNetix Pathology and Laboratories

2021

Cell Reports Methods Publication
Partnership with Allegheny Health Network
Investment from Innovation Works
First Patent Awarded

2022 – Q1-Q2

Initial Commercialization
USCAP 2022 & AACR 2022 Exhibitor/Presenter

Our Unique Value Proposition

Get two steps ahead in precision pathology

Cutting edge technology

Adaptive and
agnostic solutions

Leading academic medical center and pathology practice collaborations

Deep scientific
expertise

Subscribe to our Newsletter

* indicates required

S. Chakra Chennubhotla, PhD

PRESIDENT, CO-FOUNDER, &
CHIEF TECHNOLOGY OFFICER

Chakra earned his PhD from the Department of Computer Science at the University of Toronto specializing in computer vision, machine learning and AI. Chakra was tenured Associate Professor in the Department of Computational and Systems Biology at the University of Pittsburgh.

Chakra co-founded SpIntellx to actualize the translational potential of these Pitt IP-fueled platforms. Chakra’s experience encompasses years in both industry and academia. He was the lead PI on several National Institutes of Health and National Science Foundation grants covering broad areas of bioimaging, molecular biophysics, computational and systems biology, and spatial intratumor heterogeneity. He holds several patents and has published extensively, appearing in Science Translational Medicine and Nature Communications, among other prominent journals.

Submit your Resume

Download Whitepaper

Download Whitepaper

B. Dusty Majumdar, PhD

CHIEF EXECUTIVE OFFICER

B. Dusty Majumdar, PhD  is a seasoned leader in Precision Healthcare with more than 20 years of experience in building and successfully launching innovative technologies across oncology, multi-omics, Real-World Evidence (RWE). diagnostic imaging and liquid biopsy platforms leveraging some of the industry’s most advanced AI platforms, genomic and clinical simulations (digital twins), and emerging medical imaging technologies. Dr. Majumdar’s experience includes leading strategy and marketing as the Chief Marketing Officer (CMO) at IBM and multiple commercial and technical leadership roles at GE Healthcare, Exact Sciences and 3M. He has also led the commercial and strategic functions in a range of start-ups in the healthcare/biopharma space over the last few years.  Dr. Majumdar is a widely respected global leader in the healthcare industry and holds a Ph.D. from the University of Texas at Austin and a bachelor’s degree from the Indian Institute of Technology (IIT), Kharagpur.  He has authored several peer-reviewed scientific publications and holds multiple patents.

Joe Camaratta

Sr. VP Business Development

Joe Camaratta specializes in medical technology innovation and commercialization, taking products from concept to clinical adoption. He held executive positions for GE Healthcare and Siemens Healthcare and built businesses in medical imaging, cardiology, and oncology. He founded and led two early stage medical technology companies that apply artificial intelligence to improve clinical decision-making.

Joe holds a Master of Science degree in Computer Science from Rutgers University and a Bachelor of Science degree in Computer Science from Drexel University. He currently serves as an advisor to the Entreprenuerial Investing Program of the Crohn’s & Colitis Foundation, and the University Science Center QED Program focused on commercialization of academic innovations

D. Lansing Taylor, PhD

EXECUTIVE CHAIRMAN & CO-FOUNDER

Dr. Taylor is currently the Director of the University of Pittsburgh Drug Discovery Institute managing the collaborative programs involving clinicians, biomedical scientists, chemists, engineers and systems biologists at Pitt, Carnegie Mellon University, the University of Pittsburgh Medical Center, as well as external collaborators from academia, federal agencies and industry.

Lans was Co-Founder and CEO of Cellomics Inc., which developed and commercialized High Content Screening (HCS) that permitted single cell quantitation of multiplexed fluorescence biomarkers in arrays of cells and tissues. In addition to Cellomics, Dr. Taylor co-founded several other biotech companies, such as Biological Detection Systems, Inc. and Cernostics, Inc., and is an expert in multiplexed fluorescence and biomarker imaging.